Stockscreener 앱 받기
4.00
1.23%
-0.05
시간 외 거래:
4.01
0.010
+0.25%
전일 마감가:
$4.05
열려 있는:
$4
하루 거래량:
446.51K
Relative Volume:
1.93
시가총액:
$149.91M
수익:
$128.45M
순이익/손실:
$6.54M
주가수익비율:
80.00
EPS:
0.05
순현금흐름:
$-8.79M
1주 성능:
-8.26%
1개월 성능:
-44.60%
6개월 성능:
-43.30%
1년 성능:
-39.39%
1일 변동 폭
$3.91
$4.09
1주일 범위
$3.87
$4.50
52주 변동 폭
$3.87
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.00 | 151.78M | 128.45M | 6.54M | -8.79M | 0.05 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.42B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.64B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 44.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.51B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 22.84B | 3.18B | 1.33B | 1.04B | 27.90 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 개시 | William Blair | Outperform |
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
모두보기
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
LFCR: Barrington Research Maintains Outperform Rating with $5.50 Price Target | LFCR Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - ACCESS Newswire
Lifecore Biomedical signs third site transfer deal in five months By Investing.com - Investing.com Australia
Lifecore Biomedical Signs Commercial Manufacturing Services Agreement with Medical Aesthetics Company - marketscreener.com
Lifecore Biomedical signs third site transfer deal in five months - Investing.com
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company - Yahoo Finance
Published on: 2026-03-23 12:54:24 - baoquankhu1.vn
Lifecore stock sinks as delayed launches push growth further out - MSN
2026-03-22 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Aug Summary: Is Lifecore Biomedical Inc a strong candidate for buy and holdEarnings Overview Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Rally Mode: Is Lifecore Biomedical Inc a top pick in the sector2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights By Investing.com - Investing.com Canada
Lifecore Biomedical at KeyBanc Forum: Strategic Transformation Insights - Investing.com
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Outperform at Barrington Research - MarketBeat
Why Is Lifecore Stock Sinking Tuesday?Lifecore Biomedical (NASDAQ:LFCR) - Benzinga
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Craig-Hallum Sticks to Its Buy Rating for Lifecore Biomedical (LFCR) - The Globe and Mail
Lifecore Stock Sinks As Delayed Launches Push Growth Further Out - Sahm
Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives - simplywall.st
Lifecore Biomedical earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Lifecore Biomedical Shareholders Are Encouraged to Reach - GlobeNewswire
Lifecore Biomedical Targets 12% Revenue CAGR and 25%+ EBITDA Margin by 2029 with CDMO Growth Strategy - Minichart
Lifecore Biomedical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-03-16 - Seeking Alpha
Rate Cut: What is the implied volatility of Lifecore Biomedical Inc2026 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Lifecore Biomedical Transition period Earnings Call Transcript - MarketBeat
Lifecore Biomedical Expands CDMO Capabilities with New Aseptic Filler and Strategic Growth Initiatives - Minichart
Lifecore Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Seven Months Ended December 31, 2025 - marketscreener.com
Lifecore Biomedical Q4 Earnings Call Highlights - MarketBeat
Lifecore Biomedical’s Competitive Edge in Specialized Sterile Injectables Strengthens Pricing Leverage as Recovery Reduces EBITDA Deficit - Bitget
Lifecore Biomedical reports financial results for the fourth quarter and transition period ended December 31, 2025, and provides corporate update - marketscreener.com
LFCR: Transition period saw 20% revenue growth and improved margins; strong mid-term outlook - TradingView
Lifecore Biomedical Reports Financial Results For The Fourth Quarter And Transition Period Ended December 31, 2025, And Provides Corporate Update - TradingView
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update - The Manila Times
Lifecore Biomedical: Q4 Earnings Snapshot - marketscreener.com
Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025 - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
LFCR Earnings History & Surprises | EPS & Revenue Results | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9%Here's Why - MarketBeat
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum - The Manila Times
Stream Lifecore Biomedical’s KeyBanc healthcare fireside chat on Mar. 17 - Stock Titan
Lifecore Biomedical, Inc. to Announce Q4 and Transition Period Financial Results on March 16, 2026 - Quiver Quantitative
Lifecore Biomedical to Report Financial Results for the - GlobeNewswire
Lifecore to post Q4 and transition-period earnings on March 16 - Stock Titan
Ideas Watch: Is Lifecore Biomedical Inc forming bullish engulfing patternsLayoff News & AI Driven Stock Price Forecasts - baoquankhu1.vn
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment - Sahm
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.88%
자본화:
|
볼륨(24시간):